Back

Fenofibrate modulates cardiac energy metabolism in moderate-severe aortic stenosis: a mechanistic double-blinded randomised controlled MR trial

31 August 2024 (16:33 - 16:45)
Organised by: Logo
Congress Presentation Part of: Exploring valvular and congenital heart disease with cardiac magnetic resonance Valvular Heart Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Shveta Monga

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Severe aortic stenosis is associated with left atrial prothrombotic flow changes that persists despite successful aortic valve replacement
Doctor M. Spartera (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Right atrial and ventricular function in risk stratification of patients with pulmonary artery hypertension
Miss J. Guo (Sichuan, CN)
Abstract Slides Video
Presentation thumbnail
Impact of epicardial adipose tissue and atrial functional impairment in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement
Doctor J. Gronwald (Goettingen, DE)
Abstract Slides Video
Presentation thumbnail
LV reverse remodeling after SAVR in patients with severe symptomatic aortic stenosis: impact on the clinical outcome
Doctor M. Lima (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Exploring valvular and congenital heart disease with cardiac magnetic resonance
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 16:33 CET
You may be interested in
thumbnail
Congress Session
Exploring valvular and congenital heart disease with cardiac magnetic resonance
thumbnail
Congress Session
Advancing knowledge in aortic stenosis
thumbnail
Congress Session
Improving risk stratification in aortic stenosis: from the valve to the ventricle

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources